Merck & Co., Inc. Stock Price, News & Analysis (NYSE:MRK)

$62.17 0.08 (0.13 %)
(As of 01/17/2018 03:12 PM ET)
Previous Close$58.66
Today's Range$61.89 - $62.59
52-Week Range$53.63 - $66.80
Volume14.98 million shs
Average Volume12.58 million shs
Market Capitalization$169.55 billion
P/E Ratio60.36
Dividend Yield3.09%
Beta0.76

About Merck & Co., Inc. (NYSE:MRK)

Merck & Co., Inc. logoMerck & Co., Inc. is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company's Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells its human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed healthcare providers, such as health maintenance organizations, pharmacy benefit managers and other institutions. Vaccine products consist of preventive pediatric, adolescent and adult vaccines, primarily administered at physician offices.

Receive MRK News and Ratings via Email

Sign-up to receive the latest news and ratings for MRK and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceuticals
Sub-IndustryPharmaceuticals
SectorHealthcare
SymbolNYSE:MRK
CUSIP58933Y10
Phone+1-908-7404000

Debt

Debt-to-Equity Ratio0.57%
Current Ratio1.43%
Quick Ratio1.16%

Price-To-Earnings

Trailing P/E Ratio60.3592233009709
Forward P/E Ratio15.74
P/E Growth2.93

Sales & Book Value

Annual Sales$39.81 billion
Price / Sales4.25
Cash Flow$6.14 per share
Price / Cash10.12
Book Value$14.62 per share
Price / Book4.25

Profitability

Trailing EPS$1.03
Net Income$3.92 billion
Net Margins11.60%
Return on Equity27.08%
Return on Assets11.41%

Miscellaneous

Employees68,000
Outstanding Shares2,724,440,000

Merck & Co., Inc. (NYSE:MRK) Frequently Asked Questions

What is Merck & Co., Inc.'s stock symbol?

Merck & Co., Inc. trades on the New York Stock Exchange (NYSE) under the ticker symbol "MRK."

How often does Merck & Co., Inc. pay dividends? What is the dividend yield for Merck & Co., Inc.?

Merck & Co., Inc. announced a quarterly dividend on Tuesday, November 28th. Stockholders of record on Friday, December 15th will be given a dividend of $0.48 per share on Monday, January 8th. This represents a $1.92 dividend on an annualized basis and a dividend yield of 3.09%. The ex-dividend date is Thursday, December 14th. This is an increase from Merck & Co., Inc.'s previous quarterly dividend of $0.47. View Merck & Co., Inc.'s Dividend History.

How will Merck & Co., Inc.'s stock buyback program work?

Merck & Co., Inc. declared that its Board of Directors has authorized a share repurchase plan on Saturday, December 2nd 2017, which allows the company to repurchase $10,000,000,000.00 in shares, according to EventVestor. This repurchase authorization allows the company to buy shares of its stock through open market purchases. Stock repurchase plans are generally a sign that the company's board of directors believes its stock is undervalued.

How were Merck & Co., Inc.'s earnings last quarter?

Merck & Co., Inc. (NYSE:MRK) posted its quarterly earnings data on Friday, October, 27th. The company reported $1.11 earnings per share for the quarter, topping the Zacks' consensus estimate of $1.03 by $0.08. The firm had revenue of $10.33 billion for the quarter, compared to the consensus estimate of $10.54 billion. Merck & Co., Inc. had a net margin of 11.60% and a return on equity of 27.08%. Merck & Co., Inc.'s quarterly revenue was down 2.0% compared to the same quarter last year. During the same period in the prior year, the company earned $1.07 earnings per share. View Merck & Co., Inc.'s Earnings History.

When will Merck & Co., Inc. make its next earnings announcement?

Merck & Co., Inc. is scheduled to release their next quarterly earnings announcement on Friday, February, 2nd 2018. View Earnings Estimates for Merck & Co., Inc..

What guidance has Merck & Co., Inc. issued on next quarter's earnings?

Merck & Co., Inc. issued an update on its FY17 earnings guidance on Friday, October, 27th. The company provided earnings per share guidance of $3.91-3.97 for the period, compared to the Thomson Reuters consensus estimate of $3.88. The company issued revenue guidance of $40.0-40.5 billion, compared to the consensus revenue estimate of $40.34 billion.

Where is Merck & Co., Inc.'s stock going? Where will Merck & Co., Inc.'s stock price be in 2018?

16 analysts have issued 12-month price objectives for Merck & Co., Inc.'s stock. Their predictions range from $55.00 to $74.00. On average, they expect Merck & Co., Inc.'s share price to reach $66.87 in the next twelve months. View Analyst Ratings for Merck & Co., Inc..

What are Wall Street analysts saying about Merck & Co., Inc. stock?

Here are some recent quotes from research analysts about Merck & Co., Inc. stock:

  • 1. According to Zacks Investment Research, "Merck has made significant progress with its pipeline and is working on bringing new products to the market. New products like Keytruda and Zepatier should continue to contribute meaningfully to sales. Keytruda is gaining strong momentum from new indication of first-line lung cancer. The Keytruda development program also significantly advanced in the first half with several key regulatory approvals. Meanwhile, Merck will continue to focus on cost-cutting initiatives to drive the bottom line. However, generic competition for several drugs and pricing pressure will continue to be overhangs on the top line. Rising competition in the immuno-oncology market is also a significant concern. Merck’s shares underperformed the industry this year so far. Estimates have declined slightly ahead of the company’s Q3 earnings release. Merck has a positive record of earnings surprises in the recent quarters." (10/17/2017)
  • 2. BMO Capital Markets analysts commented, "Although expectations for EPOCH were low, we were looking for an efficacy signal in mild patients, which would have increased expectations for the APECS study. Merck's press release does not provide details regarding subgroup analysis in mild patients; however, the language suggests little to no efficacy. This lowers our probability of success for APECS from 50% to 25%, Verubecestat risk-adjusted sales from ~$5Bn in 2026 to ~$2.5Bn, and our valuation from $72 to $70. However, investors should not give up on Verubecestat; APECS has a higher chance of success." (2/15/2017)

Who are some of Merck & Co., Inc.'s key competitors?

Who are Merck & Co., Inc.'s key executives?

Merck & Co., Inc.'s management team includes the folowing people:

  • Kenneth C. Frazier, Chairman of the Board, President, Chief Executive Officer (Age 62)
  • Robert M. Davis, Chief Financial Officer, Executive Vice President (Age 50)
  • Michael J. Holston, Executive Vice President, General Counsel (Age 54)
  • Mirian M. Graddick-Weir, Executive Vice President - Human Resources (Age 62)
  • Sanat Chattopadhyay, Executive Vice President and President - Merck Manufacturing Division (Age 57)
  • Richard R. DeLuca Jr., Executive Vice President, President - Merck Animal Health (Age 54)
  • Julie Louise Gerberding M.D., Executive Vice President and Chief Patient Officer, Strategic Communications, Global Public Policy and Population Health (Age 61)
  • Roger M. Perlmutter M.D. Ph.D., Executive Vice President, President - Merck Research Laboratories (Age 65)
  • Adam H. Schechter, Executive Vice President, President - Global Human Health (Age 52)
  • Rita A. Karachun, Senior Vice President Finance - Global Controller (Age 53)

Who owns Merck & Co., Inc. stock?

Merck & Co., Inc.'s stock is owned by a number of of retail and institutional investors. Top institutional investors include Bank of Montreal Can (0.15%), Marathon Asset Management LLP (0.09%), National Pension Service (0.08%), Hexavest Inc. (0.06%), Gateway Investment Advisers LLC (0.05%) and Nisa Investment Advisors LLC (0.04%). Company insiders that own Merck & Co., Inc. stock include Adam H Schechter, C Robert Kidder, Clark Golestani, Julie L Gerberding, Kenneth C Frazier, Michael J Holston, Patricia F Russo, Rochelle B Lazarus, Thomas H Glocer, Thomas R Cech, Weir Mirian M Graddick and Wendell P Weeks. View Institutional Ownership Trends for Merck & Co., Inc..

Who sold Merck & Co., Inc. stock? Who is selling Merck & Co., Inc. stock?

Merck & Co., Inc.'s stock was sold by a variety of institutional investors in the last quarter, including Bank of Montreal Can, Sit Investment Associates Inc., Chesley Taft & Associates LLC, Exxonmobil Investment Management Inc. TX, First Citizens Bank & Trust Co., Gateway Investment Advisers LLC, Abner Herrman & Brock LLC and Nisa Investment Advisors LLC. Company insiders that have sold Merck & Co., Inc. company stock in the last year include Adam H Schechter, C Robert Kidder, Michael J Holston, Patricia F Russo, Thomas H Glocer, Thomas R Cech, Weir Mirian M Graddick and Wendell P Weeks. View Insider Buying and Selling for Merck & Co., Inc..

Who bought Merck & Co., Inc. stock? Who is buying Merck & Co., Inc. stock?

Merck & Co., Inc.'s stock was acquired by a variety of institutional investors in the last quarter, including Marathon Asset Management LLP, DnB Asset Management AS, LGT Capital Partners LTD., National Pension Service, Patriot Wealth Management Inc., Kempner Capital Management Inc., Stillwater Capital Advisors LLC and Franklin Street Advisors Inc. NC. View Insider Buying and Selling for Merck & Co., Inc..

How do I buy Merck & Co., Inc. stock?

Shares of Merck & Co., Inc. can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Merck & Co., Inc.'s stock price today?

One share of Merck & Co., Inc. stock can currently be purchased for approximately $62.17.

How big of a company is Merck & Co., Inc.?

Merck & Co., Inc. has a market capitalization of $169.55 billion and generates $39.81 billion in revenue each year. The company earns $3.92 billion in net income (profit) each year or $1.03 on an earnings per share basis. Merck & Co., Inc. employs 68,000 workers across the globe.

How can I contact Merck & Co., Inc.?

Merck & Co., Inc.'s mailing address is 2000 Galloping Hill Rd, KENILWORTH, NJ 07033-1310, United States. The company can be reached via phone at +1-908-7404000.


MarketBeat Community Rating for Merck & Co., Inc. (MRK)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  586 (Vote Outperform)
Underperform Votes:  596 (Vote Underperform)
Total Votes:  1,182
MarketBeat's community ratings are surveys of what our community members think about Merck & Co., Inc. and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Merck & Co., Inc. (NYSE:MRK) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyHoldBuyHold
Consensus Rating Score: 2.502.442.532.41
Ratings Breakdown: 0 Sell Rating(s)
8 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
8 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
5 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
2 Sell Rating(s)
6 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $66.87$66.00$70.42$69.38
Price Target Upside: 7.73% upside15.97% upside11.38% upside10.80% upside

Merck & Co., Inc. (NYSE:MRK) Consensus Price Target History

Price Target History for Merck & Co., Inc. (NYSE:MRK)

Merck & Co., Inc. (NYSE:MRK) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/17/2018BMO Capital MarketsBoost Price TargetOutperform$68.00 -> $72.00LowView Rating Details
1/16/2018Jefferies GroupReiterated RatingHold$55.00LowView Rating Details
1/16/2018SunTrust BanksUpgradeHold -> Buy$54.00 -> $72.00HighView Rating Details
11/28/2017Bank of AmericaInitiated CoverageBuy -> Buy$64.00LowView Rating Details
11/24/2017Deutsche BankLower Price TargetHold -> Hold$62.00 -> $59.00N/AView Rating Details
11/15/2017Sanford C. BernsteinReiterated RatingBuy$64.00N/AView Rating Details
11/3/2017CowenReiterated RatingHold$70.00N/AView Rating Details
11/1/2017Berenberg BankReiterated RatingHoldN/AView Rating Details
10/30/2017Leerink SwannLower Price TargetMarket Perform$70.00 -> $69.00N/AView Rating Details
10/30/2017CitigroupUpgradeBuyN/AView Rating Details
10/29/2017JPMorgan Chase & Co.Set Price TargetBuy$70.00N/AView Rating Details
10/30/2017Morgan StanleyDowngradeOverweight -> Equal Weight$56.00N/AView Rating Details
10/30/2017BarclaysDowngradeOverweight -> Equal Weight$72.00 -> $62.00N/AView Rating Details
9/5/2017Credit Suisse GroupReiterated RatingOutperform$75.00 -> $74.00LowView Rating Details
7/29/2017Piper Jaffray CompaniesSet Price TargetBuy$70.00LowView Rating Details
7/27/2017Goldman Sachs GroupReiterated RatingNeutral$70.00 -> $74.00MediumView Rating Details
1/13/2017Bryan, Garnier & CoInitiated CoverageBuyN/AView Rating Details
1/12/2017GuggenheimUpgradeNeutral -> Buy$61.63 -> $70.00N/AView Rating Details
10/27/2016ArgusReiterated RatingBuy$65.00 -> $80.00N/AView Rating Details
4/6/2016Societe GeneraleInitiated CoverageBuyN/AView Rating Details
2/5/2016S&P Equity ResearchReiterated RatingHold$56.00N/AView Rating Details
(Data available from 1/17/2016 forward)

Earnings

Merck & Co., Inc. (NYSE:MRK) Earnings History and Estimates Chart

Earnings by Quarter for Merck & Co., Inc. (NYSE:MRK)

Merck & Co., Inc. (NYSE MRK) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/2/2018$0.94N/AView Earnings Details
10/27/2017Q3 2017$1.03$1.11$10.54 billion$10.33 billionViewN/AView Earnings Details
7/28/2017Q2 17$0.87$1.01$9.75 billion$9.93 billionViewN/AView Earnings Details
5/2/2017Q1 2017$0.83$0.88$9.25 billion$9.43 billionViewListenView Earnings Details
2/2/2017Q416$0.89$0.89$10.22 billion$10.10 billionViewListenView Earnings Details
10/25/2016Q316$0.99$1.07$10.17 billion$10.50 billionViewListenView Earnings Details
7/29/2016Q216$0.91$0.93$9.79 billion$9.84 billionViewListenView Earnings Details
5/5/2016Q116$0.85$0.89$9.45 billion$9.30 billionViewN/AView Earnings Details
2/3/2016Q415$0.91$0.93$10.32 billion$10.22 billionViewListenView Earnings Details
10/27/2015Q315$0.91$0.96$10.11 billion$10.10 billionViewListenView Earnings Details
7/28/2015Q215$0.80$0.86$9.81 billion$9.80 billionViewListenView Earnings Details
4/28/2015Q115$0.75$0.85$9.04 billion$9.40 billionViewListenView Earnings Details
2/4/2015Q414$0.85$0.87$10.61 billion$10.48 billionViewListenView Earnings Details
10/27/2014Q314$0.88$0.90$10.66 billion$10.56 billionViewListenView Earnings Details
7/29/2014Q214$0.81$0.85$10.60 billion$10.93 billionViewListenView Earnings Details
4/29/2014Q114$0.79$0.88$10.44 billion$10.30 billionViewListenView Earnings Details
2/5/2014Q413$0.88$0.88$11.39 billion$11.30 billionViewListenView Earnings Details
10/28/2013Q313$0.88$0.92$11.19 billion$11.03 billionViewListenView Earnings Details
7/30/2013Q2 2013$0.82$0.84$11.22 billion$11.01 billionViewListenView Earnings Details
5/1/2013Q1 2013$0.79$0.85$11.09 million$10.70 millionViewListenView Earnings Details
2/1/2013Q4 2012$0.81$0.83$11.46 billion$11.70 billionViewListenView Earnings Details
10/26/2012Q312$0.92$0.95$11.60 billion$11.50 billionViewN/AView Earnings Details
7/27/2012$1.02$1.05ViewN/AView Earnings Details
4/27/2012$0.98$0.99ViewN/AView Earnings Details
2/2/2012$0.95$0.97ViewN/AView Earnings Details
10/28/2011$0.91$0.94ViewN/AView Earnings Details
7/29/2011$0.94$0.95ViewN/AView Earnings Details
4/29/2011$0.84$0.92ViewN/AView Earnings Details
2/3/2011$0.83$0.88ViewN/AView Earnings Details
10/29/2010Q3 2010$0.83$0.85ViewN/AView Earnings Details
7/30/2010Q2 2010$0.82$0.86ViewN/AView Earnings Details
5/4/2010Q1 2010$0.75$0.84ViewN/AView Earnings Details
2/16/2010Q4 2009$0.78$0.80ViewN/AView Earnings Details
10/22/2009Q3 2009$0.82$0.90ViewN/AView Earnings Details
7/21/2009Q2 2009$0.78$0.83ViewN/AView Earnings Details
4/21/2009Q1 2009$0.77$0.74ViewN/AView Earnings Details
2/3/2009Q4 2008$0.74$0.87ViewN/AView Earnings Details
10/22/2008Q3 2008$0.79$0.80ViewN/AView Earnings Details
7/21/2008Q2 2008$0.83$0.86ViewN/AView Earnings Details
4/21/2008Q1 2008$0.85$0.89ViewN/AView Earnings Details
1/30/2008Q4 2007$0.73$0.80ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Merck & Co., Inc. (NYSE:MRK) Earnings Estimates

Current Year EPS Consensus Estimate: $3.95 EPS
Next Year EPS Consensus Estimate: $4.08 EPS

Dividends

Merck & Co., Inc. (NYSE:MRK) Dividend Information

Most Recent Dividend:1/8/2018
Annual Dividend:$1.92
Dividend Yield:3.09%
Dividend Growth:2.20% (3 Year Average)
Payout Ratio:186.41% (Trailing 12 Months of Earnings)
48.61% (Based on This Year's Estimates)
47.06% (Based on Next Year's Estimates)
Track Record:6 Years of Consecutive Dividend Growth
Frequency:Quarterly Dividend
Dividend Payments by Quarter for Merck & Co., Inc. (NYSE:MRK)

Merck & Co., Inc. (NYSE:MRK) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
11/28/2017quarterly$0.4812/14/201712/15/20171/8/2018
7/25/2017quarterly$0.479/14/20179/15/201710/6/2017
5/23/2017quarterly$0.472.9%6/13/20176/15/20177/10/2017
2/28/2017quarterly$0.473/13/20173/15/20174/7/2017
11/22/2016quarterly$0.473.05%12/13/201612/15/20161/9/2017
7/26/2016quarterly$0.463.14%9/13/20169/15/201610/7/2016
5/24/2016quarterly$0.463.25%6/13/20166/15/20167/8/2016
2/23/2016quarterly$0.463.64%3/11/20163/15/20164/7/2016
11/24/2015quarterly$0.463.43%12/11/201512/15/20151/8/2016
7/22/2015quarterly$0.453.1%9/11/20159/15/201510/7/2015
5/26/2015quarterly$0.453.03%6/11/20156/15/20157/8/2015
2/24/2015quarterly$0.453.05%3/12/20153/16/20154/8/2015
11/25/2014quarterly$0.453.01%12/11/201412/15/20141/8/2015
7/23/2014quarterly$0.443.02%9/11/20149/15/201410/7/2014
5/27/2014quarterly$0.443.12%6/12/20146/16/20147/8/2014
2/25/2014quarterly$0.443.13%3/13/20143/17/20144/7/2014
11/26/2013quarterly$0.443.53%12/12/201312/16/20131/8/2014
7/24/2013quarterly$0.433.57%9/12/20139/16/201310/7/2013
5/28/2013quarterly$0.433.67%6/13/20136/17/20137/8/2013
2/26/2013quarterly$0.434%3/13/20133/15/20134/5/2013
(Data available from 1/1/2013 forward)

Insider Trades

Merck & Co., Inc. (NYSE MRK) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 0.25%
Institutional Ownership Percentage: 73.68%
Insider Trades by Quarter for Merck & Co., Inc. (NYSE:MRK)
Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Merck & Co., Inc. (NYSE MRK) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/16/2018Michael J. HolstonEVPSell12,500$61.63$770,375.00View SEC Filing  
1/16/2018Weir Mirian M GraddickInsiderSell60,000$61.63$3,697,800.00101,484View SEC Filing  
1/12/2018Weir Mirian M GraddickInsiderSell5,000$58.00$290,000.00101,484View SEC Filing  
11/8/2017Thomas H GlocerDirectorSell5,000$56.20$281,000.00View SEC Filing  
5/12/2017C Robert KidderDirectorSell5,000$63.54$317,700.0014,317View SEC Filing  
4/3/2017Adam H SchechterEVPSell53,850$63.48$3,418,398.00View SEC Filing  
2/8/2017Patricia F RussoDirectorSell5,000$64.42$322,100.0018,148View SEC Filing  
2/6/2017Wendell P WeeksDirectorSell5,000$64.51$322,550.005,100View SEC Filing  
2/3/2017Michael J HolstonEVPSell91,959$63.96$5,881,697.64105,559View SEC Filing  
2/3/2017Thomas R CechDirectorSell5,000$63.42$317,100.005,100View SEC Filing  
11/10/2016Kenneth C FrazierChairmanSell140,000$65.03$9,104,200.00514,957View SEC Filing  
11/7/2016Julie L GerberdingEVPSell85,523$60.02$5,133,090.4677,762View SEC Filing  
11/2/2016Rochelle B LazarusDirectorSell20,000$59.06$1,181,200.009,594View SEC Filing  
10/3/2016Weir Mirian M GraddickInsiderSell40,800$62.07$2,532,456.00128,973View SEC Filing  
9/1/2016Adam H SchechterEVPSell39,200$62.61$2,454,312.0039,200View SEC Filing  
8/10/2016Clark GolestaniEVPSell3,000$63.03$189,090.00View SEC Filing  
8/5/2016Kenneth C FrazierChairmanSell392,000$61.81$24,229,520.00760,877View SEC Filing  
7/5/2016Kenneth C FrazierCEOSell60,000$58.00$3,480,000.00554,856View SEC Filing  
7/5/2016Weir Mirian M GraddickInsiderSell45,000$57.99$2,609,550.00123,151View SEC Filing  
7/1/2016Adam H SchechterEVPSell50,000$57.69$2,884,500.0050,000View SEC Filing  
7/1/2016Weir Mirian M GraddickInsiderSell30,000$57.49$1,724,700.00162,151View SEC Filing  
5/20/2016Clark GolestaniEVPSell39,877$54.79$2,184,860.8317,083View SEC Filing  
4/14/2016Kenneth C FrazierCEOSell131,040$56.11$7,352,654.40653,517View SEC Filing  
11/4/2015Wendell P. WeeksDirectorSell5,000$55.53$277,650.00100View SEC Filing  
10/29/2015Adele D. AmbroseinsiderSell37,313$55.08$2,055,200.0419,695View SEC Filing  
10/29/2015Kenneth C. FrazierCEOSell18,666$54.69$1,020,843.54438,236View SEC Filing  
10/28/2015Peter C. WendellDirectorSell5,000$54.85$274,250.001,000View SEC Filing  
5/11/2015Adam H SchechterEVPSell10,634$60.44$642,718.96View SEC Filing  
5/8/2015Julie L GerberdingEVPSell38,368$60.99$2,340,064.32View SEC Filing  
5/4/2015Bruce N KuhlikInsiderSell56,064$60.20$3,375,052.80View SEC Filing  
4/29/2015Bruce N KuhlikInsiderSell156,902$59.82$9,385,877.64View SEC Filing  
4/29/2015Michael J HolstonEVPSell95,624$59.84$5,722,140.16View SEC Filing  
2/18/2015Kenneth C FrazierCEOSell5,164$58.67$302,971.88View SEC Filing  
2/11/2015Willie A DeeseInsiderSell135,864$58.56$7,956,195.84View SEC Filing  
2/9/2015Peter C WendellDirectorSell5,000$58.76$293,800.00View SEC Filing  
1/15/2015Adam H SchechterEVPSell74,200$62.48$4,636,016.00View SEC Filing  
1/9/2015Kenneth C FrazierCEOSell8,840$62.47$552,234.80View SEC Filing  
12/10/2014Kenneth C FrazierCEOSell9,846$60.00$590,760.00View SEC Filing  
12/8/2014Bruce N KuhlikInsiderSell50,000$62.00$3,100,000.00View SEC Filing  
11/26/2014Rochelle B LazarusDirectorSell10,000$59.63$596,300.00View SEC Filing  
11/24/2014Wendell P WeeksDirectorSell5,000$59.13$295,650.00View SEC Filing  
11/10/2014Kenneth C FrazierCEOSell10,000$57.98$579,800.00View SEC Filing  
10/10/2014Kenneth C FrazierCEOSell9,895$59.73$591,028.35View SEC Filing  
9/10/2014Kenneth C FrazierCEOSell9,814$60.48$593,550.72View SEC Filing  
8/25/2014Adam H SchechterEVPSell22,000$59.70$1,313,400.00View SEC Filing  
8/11/2014Kenneth C FrazierCEOSell10,058$57.00$573,306.00View SEC Filing  
8/4/2014Adele D AmbroseInsiderSell28,669$56.64$1,623,812.16View SEC Filing  
7/10/2014Kenneth C FrazierCEOSell9,987$58.03$579,545.61View SEC Filing  
7/7/2014Weir Mirian M GraddickInsiderSell180,047$59.16$10,651,580.52View SEC Filing  
6/27/2014Willie A DeeseInsiderSell72,290$58.26$4,211,615.40View SEC Filing  
6/10/2014Kenneth C FrazierCEOSell9,985$58.06$579,729.10View SEC Filing  
5/14/2014Adam SchechterEVPSell10,527$55.91$588,564.57View SEC Filing  
4/10/2014Kenneth FrazierCEOSell10,047$57.24$575,090.28310,494View SEC Filing  
4/4/2014Bruce KuhlikInsiderSell145,225$56.43$8,195,046.75121,845View SEC Filing  
2/14/2014Clark GolestaniEVPSell5,990$55.47$332,265.306,046View SEC Filing  
2/13/2014Bridgette HellerVPSell43,870$55.04$2,414,604.8027,587View SEC Filing  
2/11/2014Adam SchechterEVPSell18,000$55.61$1,000,980.00View SEC Filing  
2/11/2014John CananInsiderSell10,000$55.70$557,000.0010,697View SEC Filing  
2/11/2014Kenneth FrazierCEOSell41,520$54.52$2,263,670.40262,829View SEC Filing  
2/10/2014Peter WendellDirectorSell5,000$54.44$272,200.001,000View SEC Filing  
2/10/2014Willie DeeseInsiderSell50,000$54.68$2,734,000.00106,049View SEC Filing  
8/7/2013Willie DeeseInsiderSell50,638$48.55$2,458,474.90106,040View SEC Filing  
5/15/2013Adele D AmbroseInsiderSell34,208$46.66$1,596,145.28View SEC Filing  
5/13/2013Bridgette P HellerVPSell5,404$46.15$249,394.60View SEC Filing  
8/9/2012Willie A DeeseInsiderSell62,324$44.26$2,758,460.24View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Merck & Co., Inc. (NYSE MRK) News Headlines

Source:
DateHeadline
Merck & Co., Inc. (MRK) PT Raised to $72.00 at BMO Capital MarketsMerck & Co., Inc. (MRK) PT Raised to $72.00 at BMO Capital Markets
www.americanbankingnews.com - January 17 at 9:58 AM
Today’s Research Reports on Stocks to Watch: Bristol-Myers Squibb Company and Merck & Co.Today’s Research Reports on Stocks to Watch: Bristol-Myers Squibb Company and Merck & Co.
finance.yahoo.com - January 17 at 9:52 AM
Merck (MRK) Jumps: Stock Rises 5.8%Merck (MRK) Jumps: Stock Rises 5.8%
finance.yahoo.com - January 17 at 9:52 AM
Merck & Company: S&P 500’s Top Gainer on January 16Merck & Company: S&P 500’s Top Gainer on January 16
finance.yahoo.com - January 17 at 9:52 AM
Ignore the Gaps and Merck Is Ready for Further Strong GainsIgnore the Gaps and Merck Is Ready for Further Strong Gains
finance.yahoo.com - January 17 at 9:52 AM
Merck & Co., Inc.s (MRK) "Hold" Rating Reiterated at Jefferies GroupMerck & Co., Inc.'s (MRK) "Hold" Rating Reiterated at Jefferies Group
www.americanbankingnews.com - January 16 at 8:34 PM
Weir Mirian M. Graddick Sells 5,000 Shares of Merck & Co., Inc. (MRK) StockWeir Mirian M. Graddick Sells 5,000 Shares of Merck & Co., Inc. (MRK) Stock
www.americanbankingnews.com - January 16 at 7:08 PM
Insider Selling: Merck & Co., Inc. (MRK) EVP Sells 12,500 Shares of StockInsider Selling: Merck & Co., Inc. (MRK) EVP Sells 12,500 Shares of Stock
www.americanbankingnews.com - January 16 at 6:38 PM
Merck & Co., Inc. (MRK) Insider Sells $3,697,800.00 in StockMerck & Co., Inc. (MRK) Insider Sells $3,697,800.00 in Stock
www.americanbankingnews.com - January 16 at 6:36 PM
Merck Wins Big With Late-Stage Lung Cancer Drug ResultsMerck Wins Big With Late-Stage Lung Cancer Drug Results
247wallst.com - January 16 at 4:53 PM
Recent MRK NewsRecent MRK News
www.bloomberg.com - January 16 at 4:53 PM
UPDATE: Merck shares jump 7% on news of positive results from lung cancer trialUPDATE: Merck shares jump 7% on news of positive results from lung cancer trial
finance.yahoo.com - January 16 at 4:53 PM
Merck & Co., Inc. (MRK) Stock Surges on Lung Cancer Drug SuccessMerck & Co., Inc. (MRK) Stock Surges on Lung Cancer Drug Success
finance.yahoo.com - January 16 at 4:53 PM
Merck Soars as Lung Cancer Study Meets GoalsMerck Soars as Lung Cancer Study Meets Goals
finance.yahoo.com - January 16 at 4:53 PM
Early Keytruda Results Win Merck An UpgradeEarly Keytruda Results Win Merck An Upgrade
finance.yahoo.com - January 16 at 4:53 PM
Indexes Reverse Lower In Volatile Session; Bitcoin Slumps, Breakouts FadeIndexes Reverse Lower In Volatile Session; Bitcoin Slumps, Breakouts Fade
finance.yahoo.com - January 16 at 4:53 PM
Merck & Co., Inc. (MRK) Stock Surges on Lung Cancer Drug SuccessMerck & Co., Inc. (MRK) Stock Surges on Lung Cancer Drug Success
investorplace.com - January 16 at 2:42 PM
Merck & Co., Inc. (MRK) Stock Rating Upgraded by SunTrust BanksMerck & Co., Inc. (MRK) Stock Rating Upgraded by SunTrust Banks
www.americanbankingnews.com - January 16 at 10:34 AM
Merck & Co. Inc. (MRK) Is Up Sharply On Phase 3 Study ResultsMerck & Co. Inc. (MRK) Is Up Sharply On Phase 3 Study Results
www.nasdaq.com - January 16 at 10:00 AM
Mercks Keytruda succeeds in key lung cancer trialMerck's Keytruda succeeds in key lung cancer trial
finance.yahoo.com - January 16 at 10:00 AM
Mercks KEYTRUDA(R) (pembrolizumab) Significantly Improved Overall Survival and Progression-Free Survival as First-Line Treatment in Combination with Pemetrexed and Platinum Chemotherapy for Patients with Metastatic Nonsquamous Non-Small Cell Lung Cancer (KEYNOTE-189)Merck's KEYTRUDA(R) (pembrolizumab) Significantly Improved Overall Survival and Progression-Free Survival as First-Line Treatment in Combination with Pemetrexed and Platinum Chemotherapy for Patients with Metastatic Nonsquamous Non-Small Cell Lung Cancer (KEYNOTE-189)
finance.yahoo.com - January 16 at 10:00 AM
Mercks Keytruda extends lung cancer survival in combination trialMerck's Keytruda extends lung cancer survival in combination trial
finance.yahoo.com - January 16 at 10:00 AM
Merck & Co., Inc. (MRK) Expected to Post Quarterly Sales of $10.42 BillionMerck & Co., Inc. (MRK) Expected to Post Quarterly Sales of $10.42 Billion
www.americanbankingnews.com - January 13 at 12:52 PM
Merck a Top 25 Dividend Giant With 3.34% Yield (MRK)Merck a Top 25 Dividend Giant With 3.34% Yield (MRK)
www.nasdaq.com - January 12 at 4:45 PM
U.S. FDA Approves LYNPARZA® (olaparib) in Germline BRCA-Mutated Metastatic Breast CancerU.S. FDA Approves LYNPARZA® (olaparib) in Germline BRCA-Mutated Metastatic Breast Cancer
finance.yahoo.com - January 12 at 4:45 PM
Mercks Keytruda on a Roll: Can it Retain the Spark in 2018?Merck's Keytruda on a Roll: Can it Retain the Spark in 2018?
finance.yahoo.com - January 12 at 10:01 AM
Wall Street Recommendations for Mylan in January 2018Wall Street Recommendations for Mylan in January 2018
finance.yahoo.com - January 12 at 10:01 AM
What Analysts Recommend for Roche in January 2018What Analysts Recommend for Roche in January 2018
finance.yahoo.com - January 12 at 10:01 AM
Merck's Keytruda on a Roll: Can it Retain the Spark in 2018?Merck's Keytruda on a Roll: Can it Retain the Spark in 2018?
finance.yahoo.com - January 12 at 10:01 AM
Dow 30 Stock Roundup: Boeing Q4 Deliveries Up Y/Y, Success for Merck's Keytruda ComboDow 30 Stock Roundup: Boeing Q4 Deliveries Up Y/Y, Success for Merck's Keytruda Combo
finance.yahoo.com - January 12 at 10:01 AM
TEVA Stock Price Rises on Generic Launch of VireadTEVA Stock Price Rises on Generic Launch of Viread
finance.yahoo.com - January 11 at 10:18 AM
Major Pharma Short Interest Takes a PlungeMajor Pharma Short Interest Takes a Plunge
finance.yahoo.com - January 11 at 10:18 AM
Merck & Co., Inc. (MRK) Upgraded to Buy by ValuEngineMerck & Co., Inc. (MRK) Upgraded to Buy by ValuEngine
www.americanbankingnews.com - January 10 at 11:28 PM
Mylan’s Renaissance and Agila AcquisitionsMylan’s Renaissance and Agila Acquisitions
finance.yahoo.com - January 10 at 10:04 AM
Merck's Keytruda Combo Gets Breakthrough Therapy StatusMerck's Keytruda Combo Gets Breakthrough Therapy Status
finance.yahoo.com - January 10 at 10:04 AM
AbbVie’s Rova-T and the Treatment of Small Cell Lung CancerAbbVie’s Rova-T and the Treatment of Small Cell Lung Cancer
finance.yahoo.com - January 10 at 10:04 AM
Dow Analyst Moves: MRKDow Analyst Moves: MRK
www.nasdaq.com - January 9 at 4:58 PM
Merck's (MRK) Keytruda Succeeds in High-Risk Melanoma StudyMerck's (MRK) Keytruda Succeeds in High-Risk Melanoma Study
finance.yahoo.com - January 9 at 4:58 PM
Mercks (MRK) Keytruda Succeeds in High-Risk Melanoma StudyMerck's (MRK) Keytruda Succeeds in High-Risk Melanoma Study
www.zacks.com - January 9 at 9:57 AM
Merck CEO says more of drug rebates should end up with consumersMerck CEO says more of drug rebates should end up with consumers
finance.yahoo.com - January 9 at 9:57 AM
Merck CEO: We continue to work with Trump Administration ...Merck CEO: We continue to work with Trump Administration ...
finance.yahoo.com - January 9 at 9:57 AM
Merck’s KEYTRUDA® (pembrolizumab) Significantly Improved Recurrence-Free Survival Compared to Placebo as Adjuvant Therapy in Patients with Stage 3 Resected High-Risk Melanoma (EORTC1325/KEYNOTE-054)Merck’s KEYTRUDA® (pembrolizumab) Significantly Improved Recurrence-Free Survival Compared to Placebo as Adjuvant Therapy in Patients with Stage 3 Resected High-Risk Melanoma (EORTC1325/KEYNOTE-054)
finance.yahoo.com - January 8 at 10:10 AM
Key Biosimilar Approvals in 2017: Progress ReportKey Biosimilar Approvals in 2017: Progress Report
finance.yahoo.com - January 5 at 10:06 AM
2018 Bull/Bear Outlook Pfizer and Merck: Where Does Major Health Care Go From Here?2018 Bull/Bear Outlook Pfizer and Merck: Where Does Major Health Care Go From Here?
247wallst.com - January 4 at 9:54 AM
Mercks Keytruda Gets Approved for Bladder Cancer in JapanMerck's Keytruda Gets Approved for Bladder Cancer in Japan
finance.yahoo.com - January 3 at 4:58 PM
Merck's Keytruda Gets Approved for Bladder Cancer in JapanMerck's Keytruda Gets Approved for Bladder Cancer in Japan
finance.yahoo.com - January 3 at 4:58 PM
Merck to Participate at the 36th Annual J.P. Morgan Healthcare ConferenceMerck to Participate at the 36th Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - January 3 at 4:58 PM
Can Merck Regain its Mojo in 2018 After an Unimpressive 17?Can Merck Regain its Mojo in 2018 After an Unimpressive '17?
www.zacks.com - January 3 at 9:18 AM
Johnson & Johnson’s Valuation in December 2017Johnson & Johnson’s Valuation in December 2017
finance.yahoo.com - January 3 at 9:18 AM
Merck to Hold Fourth-Quarter and Full-Year 2017 Sales and Earnings Conference Call on February 2Merck to Hold Fourth-Quarter and Full-Year 2017 Sales and Earnings Conference Call on February 2
finance.yahoo.com - January 3 at 9:18 AM

SEC Filings

Merck & Co., Inc. (NYSE:MRK) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Merck & Co., Inc. (NYSE:MRK) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Merck & Co., Inc. (NYSE MRK) Stock Chart for Wednesday, January, 17, 2018

Loading chart…

This page was last updated on 1/17/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.